Bile acid sequestrant reduces glucose concentration in T2DM

Bile acid sequestrant reduces glucose concentration in T2DM
For patients with type 2 diabetes taking metformin monotherapy, the bile acid sequestrant colesevelam reduces fasting and postprandial glucose concentrations without any effects on insulin concentration, secretion, or action, according to research published online Dec. 18 in Diabetes.

(HealthDay)—For patients with type 2 diabetes taking metformin monotherapy, the bile acid sequestrant colesevelam reduces fasting and postprandial glucose concentrations without any effects on insulin concentration, secretion, or action, according to research published online Dec. 18 in Diabetes.

Galina Smushkin, M.D., of the Mayo Clinic College of Medicine in Rochester, Minn., and colleagues conducted a double-blind, placebo-controlled, parallel-group study of the effect of bile acid sequestration with colesevelam on in 38 patients with type 2 diabetes who were taking metformin monotherapy. To measure the rate of meal appearance, endogenous glucose production, and glucose disappearance, participants underwent testing before and after 12 weeks of colesevelam or placebo using a labeled triple-tracer mixed meal.

The researchers found that colesevelam treatment correlated with significantly lower fasting and postprandial , without any change in insulin concentration, secretion, or action. colesevelam treatment was not associated with changes in postprandial concentrations of glucagon-like peptide-1 (GLP-1). colesevelam was associated with no change in endogenous and glucose disappearance but was linked to a decrease in the rate of meal appearance.

"In this experiment, we demonstrate an effect of colesevelam on both fasting and postprandial glucose concentrations," the authors write. "Measurement of and action using the oral labeled and unlabeled minimal model failed to show a significant effect on insulin secretion and action. Moreover, there was no evidence that glucose lowering is produced by alterations in GLP-1 concentrations."

Daiichi-Sankyo provided grant support for the study; one author disclosed to pharmaceutical companies, including Daiichi-Sankyo, which markets colesevelam.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Insulin sensitivity normally highest after breakfast

Oct 26, 2012

(HealthDay)—In healthy people without diabetes, glucose responsiveness tends to be higher after breakfast, which may have implications for the design of closed-loop insulin delivery systems for diabetes ...

The Homburg Cream and Sugar study

Aug 29, 2011

The Homburg Cream and Sugar (HCS) study was designed to determine whether the measurement of postprandial triglyceride in addition to the assessment of glucose tolerance and traditional risk factors might improve the prediction ...

Importance of diabetes genetic variants unclear

Apr 04, 2012

(HealthDay) -- Genetic variants associated with type 2 diabetes that affect glucagon-like peptide 1 (GLP-1) are not associated with GLP-1 levels or GLP-1-induced insulin secretion in healthy individuals, according ...

Absolute incretin effect reduced in type 2 diabetes

Jun 25, 2012

(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) the absolute incretin effect is reduced compared with healthy individuals, but its relative importance is increased, particularly in first-phase ...

Recommended for you

Economic burden of prediabetes up 74 percent over five years

Nov 20, 2014

The economic burden of diabetes in America continues to climb, exceeding more than $322 billion in excess medical costs and lost productivity in 2012, or more than $1,000 for every American, according to a study being published ...

Gynoid fat resists metabolic risks of obesity

Nov 19, 2014

(HealthDay)—The differences in the developmental profiles of upper-body and lower-body fat depots may explain their opposing associations with obesity-related metabolic disease, according to research published ...

Treating diabetes one meal at a time

Nov 19, 2014

Recent estimates project that as many as one in three American adults will have diabetes in 2050. The American Diabetes Association observes November as American Diabetes Month, and this year's theme is America ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.